ARGX (argenx SE) Other Financing: $0 Mil (TTM As of Mar. 2026)


ARGX argenx SE ARGX
80 GF Score
Price $939.00
GF Value $1,382.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Other Financing?

argenx SE ARGX +3.37% 80 Other Financing is $0 Mil as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,382.72 (Significantly Undervalued). The stock has 5 warning signs investors should review.

argenx SE's Other Financing for the three months ended in Mar. 2026 was $0 Mil.

argenx SE's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

argenx SE Other Financing Historical Data

* Premium members only.

The historical data trend for argenx SE's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Other Financing Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.87 86.97 143.80 287.40 237.12

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ARGX
80GF Score
argenx SE ARGX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0 Mil mean?
argenx SE (ARGX) has a Other Financing of $0 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for argenx SE and its competitors.
Is argenx SE's Other Financing too high?
argenx SE's current Other Financing is $0 Mil. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Other Financing compare to VRTX and REGN?
argenx SE's Other Financing of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for argenx SE and its competitors. argenx SE's current Other Financing is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,382.72, compared to a current price of $939.00 — trading 32.1% below its estimated fair value. The current Other Financing is $0 Mil. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For argenx SE (ARGX), the current Other Financing is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $939.00 is trading 32.1% below its estimated GF Value™ of $1,382.72. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • Other Financing: $0 Mil
  • GF Value™: $1,382.72 vs. price of $939.00 (32.1% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score

Get the complete analysis for ARGX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$939.00
Price
$1,382.72
GF Value